NASDAQ:ORGO Organogenesis - ORGO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organogenesis Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.04 +0.01 (+0.49%) (As of 03/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.02▼$2.1050-Day Range$1.89▼$2.9352-Week Range$1.86▼$8.27Volume678,884 shsAverage Volume1.32 million shsMarket Capitalization$267.61 millionP/E Ratio15.69Dividend YieldN/APrice Target$11.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Organogenesis MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside439.2% Upside$11.00 Price TargetShort InterestBearish12.05% of Float Sold ShortDividend StrengthN/ASustainability-1.01Upright™ Environmental ScoreNews Sentiment0.74Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.20 out of 5 starsMedical Sector379th out of 1,009 stocksPharmaceutical Preparations Industry171st out of 494 stocks 3.0 Analyst's Opinion Consensus RatingOrganogenesis has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Organogenesis has a forecasted upside of 439.2% from its current price of $2.04.Amount of Analyst CoverageOrganogenesis has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.05% of the float of Organogenesis has been sold short.Short Interest Ratio / Days to CoverOrganogenesis has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Organogenesis has recently increased by 1.25%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOrganogenesis does not currently pay a dividend.Dividend GrowthOrganogenesis does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOrganogenesis has received a 64.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Wound dressings" and "Allografts" products. See details.Environmental SustainabilityThe Environmental Impact score for Organogenesis is -1.01. Previous Next 2.6 News and Social Media Coverage News SentimentOrganogenesis has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Organogenesis this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Organogenesis to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Organogenesis insiders have not sold or bought any company stock.Percentage Held by Insiders34.40% of the stock of Organogenesis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.03% of the stock of Organogenesis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Organogenesis is 15.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 122.07.Price to Earnings Ratio vs. SectorThe P/E ratio of Organogenesis is 15.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 116.30.Price to Book Value per Share RatioOrganogenesis has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Organogenesis (NASDAQ:ORGO) StockOrganogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.Read More Receive ORGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organogenesis and its competitors with MarketBeat's FREE daily newsletter. Email Address ORGO Stock News HeadlinesMarch 27, 2023 | finance.yahoo.comOrganogenesis Applauds Findings from the Office of Inspector GeneralMarch 7, 2023 | finance.yahoo.comOrganogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2022 Earnings Call TranscriptMarch 30, 2023 | WealthPop (Ad)Adam Mesh: “This Strategy Saved My Trading Career”Adam Mesh was $50,000 in the hole - and ready to quit trading for good… Until he discovered the secret to unlocking double-digit income. This strategy has averaged 64% average gains in the last three years. Adam is hosting a free session to show ordinary folks how to execute this incredible strategy. Click here to let Adam show you how it’s done. March 4, 2023 | finance.yahoo.comOrganogenesis Holdings Full Year 2022 Earnings: Revenues DisappointMarch 2, 2023 | finance.yahoo.comOrganogenesis (ORGO) Q4 2022 Earnings Call TranscriptMarch 1, 2023 | finance.yahoo.comOrganogenesis Reports Positive Interim Analysis of Phase 3 Clinical Trial of ReNu for Knee OsteoarthritisMarch 1, 2023 | finance.yahoo.comOrganogenesis Holdings Inc. Reports Fourth Quarter 2022 and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 GuidanceFebruary 9, 2023 | finance.yahoo.comOrganogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 1, 2023March 30, 2023 | WealthPop (Ad)Adam Mesh: “This Strategy Saved My Trading Career”Adam Mesh was $50,000 in the hole - and ready to quit trading for good… Until he discovered the secret to unlocking double-digit income. This strategy has averaged 64% average gains in the last three years. Adam is hosting a free session to show ordinary folks how to execute this incredible strategy. Click here to let Adam show you how it’s done. December 5, 2022 | finance.yahoo.comOrganogenesis Holdings Inc. to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech ConferenceNovember 10, 2022 | finance.yahoo.comOrganogenesis Holdings Inc. (ORGO) Q3 2022 Earnings Call TranscriptNovember 9, 2022 | finance.yahoo.comOrganogenesis Holdings Inc. Reports Third Quarter 2022 Financial ResultsNovember 9, 2022 | finance.yahoo.comOrganogenesis Holdings (NASDAQ:ORGO) shareholders have endured a 72% loss from investing in the stock a year agoOctober 30, 2022 | finance.yahoo.comOrganogenesis Holdings Inc. (ORGO)October 20, 2022 | finance.yahoo.comGlobal Amniotic Membrane Market is Predicted to Grow at a CAGR of ~5% During 2022-2031; Rise in Number of Burn Cases to Elevate Growth – Kenneth Research - Yahoo FinanceOctober 14, 2022 | finance.yahoo.comCollagen Dressings Market to Acquire Around USD 2 Billion by 2033 and to Grow at a CAGR of ~7% During 2023-2033; Rising Occurrence of Acute and Chronic Wounds Among Individuals to Elevate Market Growth – Research Nester - Yahoo FinanceOctober 12, 2022 | globenewswire.comActive Wound Care Market Size Worth US$ 10.35 Billion (2022-2030) growing at a CAGR of 4.60% | Growth Plus Reports - GlobeNewswireSeptember 29, 2022 | nasdaq.comIs Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt? - NasdaqSeptember 26, 2022 | benzinga.comOrganogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2022 Financial Results on November 9, - BenzingaSeptember 26, 2022 | finance.yahoo.comOrganogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2022 Financial Results on November 9, 2022September 26, 2022 | finance.yahoo.comWill Weakness in Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Stock Prove Temporary Given Strong Fundamentals?September 21, 2022 | businesswire.comGlobal Wound Biologics Market Report 2022: Increasing Healthcare Expenditure to Propel Growth - ResearchAndMarkets.com - Business WireSeptember 19, 2022 | globenewswire.comGlobal Advanced Wound Care Market Size is Predicted to Hit around USD 12.8 Billion by 2028 with a Registered CAGR of 5.9% from 2022 to 2028, Says Vantage Market Research - GlobeNewswireSeptember 19, 2022 | globenewswire.comThe Global Amniotic Membrane Market is expected to grow by $ 1.86 bn during 2022-2026, accelerating at a CAGR of 13.5% during the forecast period - GlobeNewswireSeptember 19, 2022 | globenewswire.comCollagen Dressings Market Estimated to Grow at ~6% CAGR during 2022-2031; Growing Diabetic Ulcer Patient Pools Rise in Geriatric Population, and Favorable Healthcare Spending Maneuver Optimistic Outlook - Research Nester - GlobeNewswireSeptember 19, 2022 | nasdaq.comValidea's Top Five Healthcare Stocks Based On Kenneth Fisher - 9/18/2022 - NasdaqSeptember 7, 2022 | benzinga.com(ORGO) – Organogenesis Holdings Inc. to Participate in the Morgan Stanley 20th Annual Global Healthcare C - BenzingaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ORGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organogenesis and its competitors with MarketBeat's FREE daily newsletter. Email Address ORGO Company Calendar Last Earnings11/09/2021Today3/30/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ORGO CUSIPN/A CIK1661181 Weborganogenesis.com Phone(781) 575-0775FaxN/AEmployees1,030Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.00 High Stock Price Forecast$11.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+439.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.13 Trailing P/E Ratio15.69 Forward P/E RatioN/A P/E GrowthN/ANet Income$15.53 million Net Margins3.66% Pretax Margin4.50% Return on Equity9.83% Return on Assets5.57% Debt Debt-to-Equity Ratio0.25 Current Ratio2.97 Quick Ratio2.64 Sales & Book Value Annual Sales$450.89 million Price / Sales0.59 Cash Flow$0.27 per share Price / Cash Flow7.68 Book Value$2.03 per share Price / Book1.00Miscellaneous Outstanding Shares131,180,000Free Float86,051,000Market Cap$267.61 million OptionableNot Optionable Beta1.55 Key ExecutivesGary S. GillheeneyPresident, Chief Executive Officer & DirectorPatrick R. BilboChief Operating OfficerDavid Charles FranciscoChief Financial OfficerLori H. FreedmanVice President & General CounselRobert CavorsiVice President - StrategyKey CompetitorsAcrivon TherapeuticsNASDAQ:ACRVAtai Life SciencesNASDAQ:ATAIAtea PharmaceuticalsNASDAQ:AVIRI-MabNASDAQ:IMABPepGenNASDAQ:PEPGView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 15,279 shares on 3/23/2023Ownership: 0.017%Alliancebernstein L.P.Bought 18,064 shares on 2/16/2023Ownership: 0.108%State of WyomingBought 23,935 shares on 2/16/2023Ownership: 0.043%Legal & General Group PlcBought 3,903 shares on 2/15/2023Ownership: 0.128%Jane Street Group LLCBought 13,604 shares on 2/15/2023Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions ORGO Stock - Frequently Asked Questions Should I buy or sell Organogenesis stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ORGO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORGO, but not buy additional shares or sell existing shares. View ORGO analyst ratings or view top-rated stocks. What is Organogenesis' stock price forecast for 2023? 2 brokerages have issued 12 month target prices for Organogenesis' stock. Their ORGO share price forecasts range from $11.00 to $11.00. On average, they expect the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 439.2% from the stock's current price. View analysts price targets for ORGO or view top-rated stocks among Wall Street analysts. How have ORGO shares performed in 2023? Organogenesis' stock was trading at $2.69 on January 1st, 2023. Since then, ORGO shares have decreased by 24.2% and is now trading at $2.04. View the best growth stocks for 2023 here. When is Organogenesis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our ORGO earnings forecast. How were Organogenesis' earnings last quarter? Organogenesis Holdings Inc. (NASDAQ:ORGO) announced its earnings results on Tuesday, November, 9th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.06 by $0.03. The company had revenue of $113.75 million for the quarter, compared to analysts' expectations of $112.10 million. Organogenesis had a trailing twelve-month return on equity of 9.83% and a net margin of 3.66%. During the same period in the prior year, the firm earned $0.19 EPS. What ETFs hold Organogenesis' stock? ETFs with the largest weight of Organogenesis (NASDAQ:ORGO) stock in their portfolio include Janus Henderson Small Cap Growth Alpha ETF (JSML), Strategas Global Policy Opportunities ETF (SAGP), Syntax Stratified SmallCap ETF (SSLY) and Invesco S&P SmallCap Health Care ETF (PSCH). What guidance has Organogenesis issued on next quarter's earnings? Organogenesis updated its FY 2023 earnings guidance on Wednesday, March, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $450.00 million-$462.00 million, compared to the consensus revenue estimate of $501.90 million. What other stocks do shareholders of Organogenesis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Organogenesis investors own include Strongbridge Biopharma (SBBP), vTv Therapeutics (VTVT), Cerecor (CERC), Marker Therapeutics (MRKR), Matinas BioPharma (MTNB), OPKO Health (OPK), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), DURECT (DRRX) and Evofem Biosciences (EVFM). What is Organogenesis' stock symbol? Organogenesis trades on the NASDAQ under the ticker symbol "ORGO." Who are Organogenesis' major shareholders? Organogenesis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Soleus Capital Management L.P. (5.62%), AQR Capital Management LLC (1.67%), Morgan Stanley (1.51%), Millennium Management LLC (1.32%), Geode Capital Management LLC (1.12%) and Assenagon Asset Management S.A. (1.10%). Insiders that own company stock include 2016 Organo 10-Year Grat U/ Gn, Albert Erani, Antonio S Montecalvo, Arthur S Leibowitz, Avista Capital Managing Member, Dennis Erani, Gary S Gillheeney, Gary S Gillheeney, Glenn H Nussdorf, Glenn H Nussdorf, Michael W Katz, Michael W Katz, Starr Wisdom and Wayne D Mackie. View institutional ownership trends. How do I buy shares of Organogenesis? Shares of ORGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Organogenesis' stock price today? One share of ORGO stock can currently be purchased for approximately $2.04. How much money does Organogenesis make? Organogenesis (NASDAQ:ORGO) has a market capitalization of $267.61 million and generates $450.89 million in revenue each year. The company earns $15.53 million in net income (profit) each year or $0.13 on an earnings per share basis. How many employees does Organogenesis have? The company employs 1,030 workers across the globe. How can I contact Organogenesis? Organogenesis' mailing address is 85 Dan Road, Canton MA, 02021. The official website for the company is organogenesis.com. The company can be reached via phone at (781) 575-0775 or via email at organoir@westwicke.com. This page (NASDAQ:ORGO) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.